预约演示

更新于：2025-09-26

Amisulpride

氨磺必利

更新于：2025-09-26

概要

基本信息

药物类型

小分子化药

别名

4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride

+ [19]

靶点

D2 receptor x D3 receptor

作用方式

拮抗剂

作用机制

D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂)

治疗领域

神经系统疾病其他疾病

在研适应症

术后恶心呕吐精神分裂症急性精神分裂症+ [5]

非在研适应症

躁郁症1型终末期肾脏病躁狂

原研机构

Acacia Research Corp.

在研机构

华益泰康药业股份有限公司Sanofi-Aventis Australia Pty Ltd.北京普德康利医药科技发展有限公司

+ [7]

非在研机构

SanofiAcacia Pharma Group Ltd.KYE Pharmaceuticals, Inc.

权益机构

Eagle Pharmaceuticals, Inc.Acacia Pharma Group Ltd.

最高研发阶段批准上市

首次获批日期

澳大利亚 (2002-02-01),

急性精神分裂症慢性精神分裂症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H27N3O4S

InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N

CAS号71675-85-9

关联

106

项与氨磺必利相关的临床试验

CTR20252649

/ Recruiting临床1期

氨磺必利注射液在中国健康受试者中单次给药的药代动力学特征和安全性的Ⅰ期临床研究

研究在中国成年健康受试者中： 1)通过测定单次静脉注射不同剂量（5 mg、10 mg、15 mg）北京普德康利医药科技发展有限公司研制的氨磺必利注射液（4mL:10mg）后，血浆中活性成分——氨磺必利药物浓度变化，估算单次给药的药代动力学参数，并分析氨磺必利单次给药药代动力学特征； 2)观察单次静脉注射不同剂量（5 mg、10 mg、15 mg）氨磺必利注射液的安全性。

开始日期2025-07-03

申办/合作机构

北京普德康利医药科技发展有限公司

CTRI/2025/04/085584

/ Not yet recruiting临床4期IIT

A prospective study comparing the efficacy of amisulpride,palanosetron and ondansetron with dexamethasone for postoperative nausea and vomiting in patients coming for elective laparoscopic cholecystectomy under general anaesthesia-a randomised control trial - Nil

开始日期2025-05-05

申办/合作机构-

NCT06887621

/ Recruiting临床2期IIT

Patients at High Risk for Postoperative Nausea and Vomiting Undergoing Gynecological Surgery: Efficacy of Oral Amisulpride in Combination With Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial

Amisulpride is a potent antagonist of dopamine D2 and D3 receptors, both implicated in the emetic response when activated. It is currently used intravenously for the prevention of chemotherapy-induced and postoperative nausea and vomiting (PONV), but this route has a short half-life time of 4 to 5 hours, could be expensive, causes infusion-related pain, and is not available in Brazil. Some of these limitations could be overcome by the preemptive use of an oral formulation. At present, there are no data regarding the use of oral amisulpride for PONV, which is an affordable and painless option with half-life time of 12 hours. We propose a quadruple-blind clinical trial involving patients undergoing gynecological surgery aged 18 years and older, and assessed as being at high risk for PONV according to the Apfel Score (score 3 or 4). The primary outcome of this study is to evaluate complete response to PONV up to 24h, comparing the efficacy of adding 50 mg oral amisulpride as a third antiemetic agent to the standard institutional protocol at the Hospital da Mulher of São Paulo (IV dexamethasone 10 mg + IV ondansetron 4 mg) for laparoscopic surgeries. Secondary outcomes will evaluate (1) nausea, (2) vomiting, (3) nausea and vomiting, (4) use of rescue treatment, (5) overall adverse events, and (6) adverse events.

开始日期2025-04-10

申办/合作机构

Instituto do Cancer do Estado de Sao Paulo

[+1]

100 项与氨磺必利相关的临床结果

登录后查看更多信息

100 项与氨磺必利相关的转化医学

登录后查看更多信息

100 项与氨磺必利相关的专利（医药）

登录后查看更多信息

2,042

项与氨磺必利相关的文献（医药）

2025-12-01·Water Research X

Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive

作者: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice

The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.It indicate that the conventional biol. treatment is insufficient, with median removal rates below 50% for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80% for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80% removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.

2025-11-01·JOURNAL OF PSYCHIATRIC RESEARCH

Determinants of real-world functioning in first-episode psychosis patients receiving 4 weeks of amisulpride treatment: findings from the multinational OPTiMiSE study

Article

作者: Bobes, Julio ; Sáiz, Pilar Alejandra ; García-Portilla González, María Paz ; Rodriguez-Jimenez, Roberto ; García-Álvarez, Leticia ; Winter, Inge

INTRODUCTION:

Identifying factors that promote real-world functioning in patients with first-episode psychosis (FEP) may guide the development of effective interventions.

OBJECTIVE:

To determine factors associated with real-world functioning in FEP patients after 4 weeks of amisulpride treatment.

METHODS:

A total of 354 FEP patients were included. Baseline assessments covered socio-demographic and clinical data, the Positive and Negative Syndrome Scale (PANSS), and the Calgary Depression Rating Scale. Real-world functioning was assessed at week 4 using the Personal and Social Performance scale.

RESULTS:

After 4 weeks, 69.2 % of patients were in remission, while 27.7 % showed good real-world functioning. More years of education (estimator = 0.54) and lower baseline levels of depressive (estimator = -0.37) and amotivational symptoms (estimator = -0.79) were protective factors for general functioning. Non-remission at week 4 (estimator = 15.33) significantly increased the risk of poor functioning. Amotivation and non-remission were also linked to worse outcomes in work and social relationships areas. Regarding self-care, more years of education (estimator = -0.04), fewer depressive symptoms (estimator = 0.03), and not using cannabis (estimator = -0.19) were protective. For aggressive behavior functioning, higher levels of diminished expression (estimator = -0.03), lower levels of depressive symptoms (estimator = 0.02) and positive symptoms (estimator = 0.02), as well as remission at week 4 (estimator = -0.37), were protective.

CONCLUSION:

Negative symptoms, specifically amotivation and diminished expression, play a key role in real-world functioning. Amotivation impacts general and domain-specific functioning, while positive symptoms and diminished expression mainly affect aggressive behaviors area.

2025-10-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Harnessing integrated bioinformatics to identify new diagnostic and therapeutic strategies for heart failure

Article

作者: Wang, Ruilin ; Shang, Min ; Sun, Shuo ; Fu, Guosheng ; Huang, Chengchen ; Lai, Chaojie

Heart failure (HF) is a life-threatening condition that poses a significant challenge on public health, particularly among the elder populations. To develop new diagnostic and therapeutic strategies for HF, we analyzed large-scale transcriptome sequencing data from HF patients as an exploratory approach. We identified 18 HF-related genes and developed a robust scoring model for HF diagnosis, by applying two machine learning algorithms for data analysis. Meanwhile, we evaluated and compared the predictive abilities of three bioinformatics methods in identifying potential HF treatment drugs. Significantly, an unconventional network-based proximity analysis, integrating multidimensional drug target information, outperformed other methods in the assessment of predictive ability. To validate these findings, we tested several candidate drugs in a mouse model transitioning from acute myocardial infarction (MI) to chronic HF. Among the candidates, mirtazapine exhibited cardioprotective effects in both early (1-week) post-MI and chronic HF (4-week post-MI) settings, while cabergoline showed potential efficacy primarily in the early post-MI phase. Additionally, the screened triamterene, used as a positive control, exhibited protective effects in both early post-MI and chronic HF stages. Mechanistic studies revealed that growth factor receptor-bound protein 14 and Ras-related protein Rab-3A were critical to the observed cardioprotection. These findings provide valuable evidence and insights for exploring potential therapeutic agents for HF treatment.

169

项与氨磺必利相关的新闻（医药）

2025-09-25

·GlobeNewswire-Health Care

LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September 10, 2025. The Company believes Mr. Kane and Ms. Hemrajani add valuable expertise in finance, business development, product commercialization, and corporate strategy to its Board of Directors as the Company advances its lead product candidate, LB-102, into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. LB Pharmaceuticals is building a pipeline that leverages the broad therapeutic potential of LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. “Ms. Hemrajani and Mr. Kane have complementary strengths that will accelerate our strategic growth as we approach the initiation of two important clinical trials early next year,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “Ms. Hemrajani’s experience in financial operations and corporate governance and Mr. Kane’s proven track record of commercializing new therapies make them outstanding additions to our Board of Directors. Their guidance will be invaluable as we work to fulfill our mission of bringing safer, more effective neuropsychiatric treatments to patients.” Mr. Kane brings over three decades of biopharmaceutical leadership to the Board. He is currently President and CEO of Uniquity Bio. He was previously President and CCO at Anthos Therapeutics (through its acquisition by Novartis), CCO at Karuna Therapeutics, where he led the commercialization strategy for Cobenfy, and held senior roles at BioXcel Therapeutics and Allergan, where he helped launch multiple leading branded therapeutics including Namzaric, Vraylar, and Ubrelvy, and at Pfizer, where he was instrumental in the success of multiple blockbuster products, including Zoloft, Zyrtec and Celebrex. He holds an MBA from The Wharton School and a B.A. in Government from Connecticut College. Mr. Kane commented, “LB Pharmaceuticals has potential to make a significant impact in neuropsychiatric care. LB‑102 offers a compelling balance of clinical activity, tolerability, and simplicity of dosing—qualities that matter deeply to prescribers and patients alike – and I look forward to supporting the Company’s efforts to deliver on this promising potential.” Ms. Hemrajani currently serves on the boards of directors of ALX Oncology, BioAge Labs, and MaxCyte. Her previous roles include CEO of Aravive, COO and CFO of Arcus Biosciences, COO of RAPT Therapeutics, and CFO of Sagimet Biosciences. She also formerly led Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen), and Business Development at Exelixis. She holds a B.S. in Economics and Computer Science from the University of Michigan and an MBA from Kellogg School of Management at Northwestern University. “I am excited to partner with LB Pharmaceuticals at this critical phase as they transition toward late-stage Phase 3 development. The data from the Phase 2 clinical trial of LB-102 provide a strong foundation for further development, and I look forward to helping guide the Company’s path toward its ultimate goal of delivering meaningful impact for patients and physicians alike.” About LB Pharmaceuticals LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. About LB-102 LB-102 is a Phase 3-ready oral, small molecule and a methylated derivative of amisulpride. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. The Phase 2 trial demonstrated statistically significant benefit versus placebo at all doses studied, a potentially class leading safety profile among D2 antagonists and partial agonists, and positive effects on negative symptoms and cognition. LB-102 is advancing into a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression. Additional expansion opportunities for LB-102 could include major depressive disorder (MDD), predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia. Cautionary Note Regarding Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102, the Company’s ability to commercialize LB-102, if approved; and continuing advancement of LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and its other documents to be subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. ContactsMedia:Michael TattoryLifeSci Communications Mtattory@lifescicomms.com Investor Relations: ir@lbpharma.us

临床2期高管变更临床结果临床3期上市批准

2025-09-15

·国家药品监督管理局

2025年09月15日药品批准证明文件送达信息

2022年11月1日起，行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照，按照相关提示自行打印。序号受理号药品名称申请人批准文号批准日期1CXHS2400097、CXHB2500087安瑞克芬注射液海思科医药集团股份有限公司国药准字H202500142025年09月09日2CXHS2500005枸橼酸伏维西利胶囊锦州奥鸿药业有限责任公司国药准字H202500232025年09月09日3CXHS2500006枸橼酸伏维西利胶囊锦州奥鸿药业有限责任公司国药准字H202500242025年09月09日4CXSS2400041Sabin株脊髓灰质炎灭活疫苗（Vero细胞）北京民海生物科技有限公司国药准字S202500512025年09月09日5CXZS2400036枇杷清肺饮颗粒河北万岁药业有限公司国药准字C202500112025年09月09日6CYHB2402063恩格列净片山东新时代药业有限公司国药准字H202581972025年09月12日7CYHB2450141注射用头孢他啶重庆吉斯瑞制药有限责任公司国药准字H202581962025年09月12日8CYHB2450142注射用头孢他啶重庆吉斯瑞制药有限责任公司国药准字H202581952025年09月12日9CYHB2450547头孢泊肟酯片浙江普洛巨泰药业有限公司————2025年09月12日10CYHB2501287甲苯磺酸艾多沙班片辰欣药业股份有限公司————2025年09月12日11CYHB2501324盐酸多巴酚丁胺注射液浙江沣华医药科技有限公司————2025年09月12日12CYHS2202121国、CYHB2500713水合氯醛灌肠剂海南天盛保和生物科技有限公司国药准字H202553872025年09月09日13CYHS2202122国、CYHB2501017水合氯醛灌肠剂海南天盛保和生物科技有限公司国药准字H202553882025年09月09日14CYHS2300221马来酸奈拉替尼片湖南科伦制药有限公司国药准字H202553372025年09月09日15CYHS2300737托拉塞米注射液江苏睿实生物科技有限公司国药准字H202554262025年09月09日16CYHS2300738托拉塞米注射液江苏睿实生物科技有限公司国药准字H202554272025年09月09日17CYHS2301749盐酸多巴胺注射液酒泉大得利制药股份有限公司国药准字H202554542025年09月09日18CYHS2302225西格列汀二甲双胍缓释片越洋医药开发（广州）有限公司国药准字H202554282025年09月09日19CYHS2302380波生坦片北京颐康兴医药有限公司国药准字H202553892025年09月09日20CYHS2302851盐酸甲氧氯普胺注射液四川邈济生物医药科技有限公司国药准字H202553712025年09月09日21CYHS2302985碳酸氢钠注射液江西璟瑞药业有限公司国药准字H202553902025年09月09日22CYHS2303053磷酸奥司他韦干混悬剂海南葫芦娃药业集团股份有限公司国药准字H202554552025年09月09日23CYHS2303085吡格列酮二甲双胍片（15mg/500mg）江苏安必生制药有限公司国药准字H202553572025年09月09日24CYHS2303124注射用头孢哌酮钠舒巴坦钠广东粤和泽药物研究有限公司国药准字H202553972025年09月09日25CYHS2303125注射用头孢哌酮钠舒巴坦钠广东粤和泽药物研究有限公司国药准字H202553982025年09月09日26CYHS2303156、CYHB2500607盐酸甲氧氯普胺注射液朗天药业（湖北）有限公司国药准字H202553992025年09月09日27CYHS2303337盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553912025年09月09日28CYHS2303338盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553922025年09月09日29CYHS2303339盐酸左沙丁胺醇雾化吸入溶液苏州弘森药业股份有限公司国药准字H202553932025年09月09日30CYHS2303407米诺地尔搽剂辽宁新高制药有限公司国药准字H202553382025年09月09日31CYHS2303409坎地沙坦酯氢氯噻嗪片（Ⅱ）浙江华海药业股份有限公司国药准字H202554562025年09月09日32CYHS2303497复方匹可硫酸钠颗粒北京民康百草医药科技有限公司国药准字H202554572025年09月09日33CYHS2303549乳果糖口服溶液国药控股星鲨制药（厦门）有限公司国药准字H202553722025年09月09日34CYHS2303550乳果糖口服溶液国药控股星鲨制药（厦门）有限公司国药准字H202553732025年09月09日35CYHS2303575酮咯酸氨丁三醇注射液重庆莱美药业股份有限公司国药准字H202553582025年09月09日36CYHS2303585甲磺酸伊马替尼片浙江麒正药业有限公司国药准字H202553392025年09月09日37CYHS2303589氯化钾注射液江西博泰药业有限公司国药准字H202554582025年09月09日38CYHS2303590氯化钾注射液江西博泰药业有限公司国药准字H202554592025年09月09日39CYHS2303625碘佛醇注射液重庆圣华曦药业股份有限公司国药准字H202554602025年09月09日40CYHS2400026氟比洛芬酯注射液宜昌人福药业有限责任公司国药准字H202554002025年09月09日41CYHS2400047乳果糖口服溶液广西维威制药有限公司国药准字H202554292025年09月09日42CYHS2400048乳果糖口服溶液广西维威制药有限公司国药准字H202554302025年09月09日43CYHS2400051盐酸甲氧氯普胺注射液中润药业有限公司国药准字H202554012025年09月09日44CYHS2400147法莫替丁注射液锦州奥鸿药业有限责任公司国药准字H202553402025年09月09日45CYHS2400262糠酸莫米松乳膏重庆华邦制药有限公司国药准字H202553592025年09月09日46CYHS2400263糠酸莫米松乳膏重庆华邦制药有限公司国药准字H202553602025年09月09日47CYHS2400267利多卡因凝胶贴膏陕西东科制药有限责任公司国药准字H202553412025年09月09日48CYHS2400280盐酸美金刚口服溶液沈阳天邦药业有限公司国药准字H202554022025年09月09日49CYHS2400306硫代硫酸钠注射液南京海辰药业股份有限公司国药准字H202554032025年09月09日50CYHS2400322注射用醋酸地加瑞克正大天晴药业集团股份有限公司国药准字H202553422025年09月09日51CYHS2400323注射用醋酸地加瑞克正大天晴药业集团股份有限公司国药准字H202553432025年09月09日52CYHS2400333盐酸戊乙奎醚注射液国药集团工业有限公司廊坊分公司国药准字H202553612025年09月09日53CYHS2400384熊去氧胆酸胶囊山东淄博新达制药有限公司国药准字H202553442025年09月09日54CYHS2400427他达拉非片山东汇泽生物制药有限公司国药准字H202553742025年09月09日55CYHS2400478氨氯地平贝那普利胶囊东阳祥昇医药科技有限公司国药准字H202553752025年09月09日56CYHS2400491甲氨蝶呤注射液吉斯美（武汉）制药有限公司国药准字H202554312025年09月09日57CYHS2400492甲氨蝶呤注射液吉斯美（武汉）制药有限公司国药准字H202554322025年09月09日58CYHS2400531夫西地酸乳膏湖北成田药业有限公司国药准字H202553622025年09月09日59CYHS2400552二甲双胍恩格列净片（Ⅰ）山东新时代药业有限公司国药准字H202554042025年09月09日60CYHS2400553二甲双胍恩格列净片（Ⅵ）山东新时代药业有限公司国药准字H202554052025年09月09日61CYHS2400556盐酸普罗帕酮注射液成都瑞尔医药科技有限公司国药准字H202554612025年09月09日62CYHS2400557注射用盐酸罗沙替丁醋酸酯浙江华海药业股份有限公司国药准字H202554062025年09月09日63CYHS2400625盐酸克林霉素棕榈酸酯颗粒广州一品红制药有限公司国药准字H202553762025年09月09日64CYHS2400628吡仑帕奈口服混悬液锦州奥鸿药业有限责任公司国药准字H202553942025年09月09日65CYHS2400638碘佛醇注射液重庆煜洋药业有限公司国药准字H202554332025年09月09日66CYHS2400662盐酸奥洛他定颗粒成都倍特药业股份有限公司国药准字H202554622025年09月09日67CYHS2400684马来酸氯苯那敏注射液辽宁海神联盛制药有限公司国药准字H202554452025年09月09日68CYHS2400704盐酸鲁拉西酮片山东新时代药业有限公司国药准字H202553452025年09月09日69CYHS2400712己酮可可碱缓释片普济生物科技（台州）有限公司国药准字H202553772025年09月09日70CYHS2400730、CYHB2501194托吡酯口服溶液梦阳药业（上海）有限公司国药准字H202553782025年09月09日71CYHS2400826富马酸伏诺拉生片重庆圣华曦药业股份有限公司国药准字H202554072025年09月09日72CYHS2400856吡仑帕奈片锦州奥鸿药业有限责任公司国药准字H202553632025年09月09日73CYHS2400857吡仑帕奈片锦州奥鸿药业有限责任公司国药准字H202553642025年09月09日74CYHS2400877盐酸贝尼地平片辰欣药业吉林有限公司国药准字H202554342025年09月09日75CYHS2400881替米沙坦氨氯地平片（II）成都奥邦药业有限公司国药准字H202553652025年09月09日76CYHS2400882替米沙坦氨氯地平片成都奥邦药业有限公司国药准字H202553792025年09月09日77CYHS2400893吗啉硝唑氯化钠注射液石家庄四药有限公司国药准字H202554462025年09月09日78CYHS2400906氨磺必利口服溶液仁合益康集团有限公司国药准字H202554632025年09月09日79CYHS2400914克立硼罗软膏浙江赛默制药有限公司国药准字H202553802025年09月09日80CYHS2400916法莫替丁注射液武汉福星生物药业有限公司国药准字H202553462025年09月09日81CYHS2400918琥珀酸普芦卡必利片漯河市汇创医药有限公司国药准字H202554472025年09月09日82CYHS2400934替格瑞洛片安若维他药业泰州有限公司国药准字H202554352025年09月09日83CYHS2400935替格瑞洛片安若维他药业泰州有限公司国药准字H202554362025年09月09日84CYHS2400940重酒石酸去甲肾上腺素注射液海南美康达药业有限公司国药准字H202553812025年09月09日85CYHS2400980己酮可可碱缓释片广东君康药业有限公司国药准字H202553472025年09月09日86CYHS2400995吡格列酮二甲双胍片（15mg/850mg）北京福元医药股份有限公司国药准字H202553662025年09月09日87CYHS2401007、CYHB2500786二甲双胍恩格列净片（Ⅰ）河南福森药业有限公司国药准字H202554082025年09月09日88CYHS2401048米拉贝隆缓释片南京易亨制药有限公司国药准字H202554642025年09月09日89CYHS2401087左氧氟沙星注射液陕西博森生物制药股份集团有限公司国药准字H202554092025年09月09日90CYHS2401106西咪替丁注射液石家庄迪斯凯威医药科技有限公司国药准字H202554102025年09月09日91CYHS2401133丙酸氟替卡松吸入粉雾剂润生药业有限公司国药准字H202554652025年09月09日92CYHS2401148沙库巴曲缬沙坦钠片迪沙药业集团有限公司国药准字H202553482025年09月09日93CYHS2401206盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司国药准字H202553492025年09月09日94CYHS2401208盐酸替罗非班氯化钠注射液安徽双鹤药业有限责任公司国药准字H202553502025年09月09日95CYHS2401236卡格列净片沐邦（北京）医药科技有限公司国药准字H202553512025年09月09日96CYHS2401256盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554112025年09月09日97CYHS2401257盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554122025年09月09日98CYHS2401258盐酸布比卡因注射液山东诚创蓝海医药科技有限公司国药准字H202554132025年09月09日99CYHS2401265乳果糖口服溶液江西远超医药科技有限公司国药准字H202553822025年09月09日100CYHS2401266乳果糖口服溶液江西远超医药科技有限公司国药准字H202553832025年09月09日101CYHS2401270磷酸奥司他韦胶囊山东鲁抗三叶制药有限公司国药准字H202554142025年09月09日102CYHS2401277注射用头孢他啶阿维巴坦钠安徽威尔曼制药有限公司国药准字H202554482025年09月09日103CYHS2401280枸橼酸西地那非口崩片山东新华制药股份有限公司国药准字H202553522025年09月09日104CYHS2401288他达拉非片辽宁鑫善源药业有限公司国药准字H202554152025年09月09日105CYHS2401289他达拉非片辽宁鑫善源药业有限公司国药准字H202554162025年09月09日106CYHS2401290他达拉非片辽宁鑫善源药业有限公司国药准字H202554172025年09月09日107CYHS2401294马来酸氟伏沙明片石家庄龙泽制药股份有限公司国药准字H202554662025年09月09日108CYHS2401297布南色林片山东京卫制药有限公司国药准字H202554672025年09月09日109CYHS2401306枸橼酸托瑞米芬片重庆圣华曦药业股份有限公司国药准字H202554182025年09月09日110CYHS2401311普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553672025年09月09日111CYHS2401312普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553682025年09月09日112CYHS2401314普瑞巴林口服溶液海南斯达制药有限公司国药准字H202553692025年09月09日113CYHS2401319盐酸利多卡因注射液南京泽恒医药技术开发有限公司国药准字H202554682025年09月09日114CYHS2401323培哚普利氨氯地平片（Ⅰ）江西施美药业股份有限公司国药准字H202554192025年09月09日115CYHS2401324培哚普利氨氯地平片（Ⅲ）江西施美药业股份有限公司国药准字H202554202025年09月09日116CYHS2401325培哚普利氨氯地平片（Ⅱ）江西施美药业股份有限公司国药准字H202554212025年09月09日117CYHS2401401双醋瑞因胶囊赛灵药业科技集团股份有限公司国药准字H202553952025年09月09日118CYHS2401426盐酸贝尼地平片深圳大佛药业股份有限公司国药准字H202554372025年09月09日119CYHS2401427盐酸贝尼地平片深圳大佛药业股份有限公司国药准字H202554382025年09月09日120CYHS2401441法莫替丁注射液成都倍特药业股份有限公司国药准字H202553532025年09月09日121CYHS2401442二甲双胍恩格列净片（Ⅴ）北京双鹭药业股份有限公司国药准字H202554492025年09月09日122CYHS2401443二甲双胍恩格列净片（Ⅰ）北京双鹭药业股份有限公司国药准字H202554502025年09月09日123CYHS2401452盐酸去氧肾上腺素注射液云南龙海天然植物药业有限公司国药准字H202554692025年09月09日124CYHS2401493葡萄糖酸钙氯化钠注射液石家庄四药有限公司国药准字H202553962025年09月09日125CYHS2401546拉莫三嗪分散片仁合益康集团有限公司国药准字H202553542025年09月09日126CYHS2401548左炔诺孕酮片武汉九珑人福药业有限责任公司国药准字H202554222025年09月09日127CYHS2401581注射用阿糖胞苷石家庄迪斯凯威医药科技有限公司国药准字H202554392025年09月09日128CYHS2401622塞来昔布胶囊大桐制药（中国）有限责任公司国药准字H202554512025年09月09日129CYHS2401678巴瑞替尼片杭州民生药业股份有限公司国药准字H202554702025年09月09日130CYHS2401714尼可地尔片重庆莱美药业股份有限公司国药准字H202554522025年09月09日131CYHS2401734注射用硫酸艾沙康唑合肥亿帆生物制药有限公司国药准字H202554402025年09月09日132CYHS2401737甲硝唑凝胶合肥启旸生物医药科技有限公司国药准字H202554412025年09月09日133CYHS2401753盐酸丙卡特罗吸入溶液北京海步医药科技有限公司国药准字H202554232025年09月09日134CYHS2401803卡铂注射液中寰医药有限公司国药准字H202553552025年09月09日135CYHS2401839注射用亚胺培南西司他丁钠深圳华药南方制药有限公司国药准字H202553702025年09月09日136CYHS2401939硫酸艾沙康唑胶囊杭州沐源生物医药科技有限公司国药准字H202554532025年09月09日137CYHS2401960盐酸戊乙奎醚注射液广州瑞尔医药科技有限公司国药准字H202553842025年09月09日138CYHS2401961磷/碳酸氢钠血滤置换液山东齐都药业有限公司国药准字H202553852025年09月09日139CYHS2402067盐酸阿罗洛尔片成都苑东生物制药股份有限公司国药准字H202554242025年09月09日140CYHS2402128恩格列净片康臣药业（内蒙古）有限责任公司国药准字H202553562025年09月09日141CYHS2402307替格瑞洛片浙江京新药业股份有限公司国药准字H202554422025年09月09日142CYHS2402308替格瑞洛片浙江京新药业股份有限公司国药准字H202554432025年09月09日143CYHS2402345普拉洛芬滴眼液鲁南贝特制药有限公司国药准字H202554442025年09月09日144CYHS2403653地夸磷索钠滴眼液武汉先路医药科技股份有限公司国药准字H202554252025年09月09日145CYHS2403793布比卡因脂质体注射液湖南科伦制药有限公司国药准字H202446862025年09月09日146CYHS2403794布比卡因脂质体注射液湖南科伦制药有限公司国药准字H202446852025年09月09日147CYHS2403864氧江苏宝祥气体有限公司国药准字H202553862025年09月09日148CYZB2501317脉络通葵花药业集团（佳木斯）有限公司————2025年09月12日149CYZB2501818跌打活血胶囊江西远超医药科技有限公司————2025年09月12日150CYZB2501820牛黄清心丸(局方)河南乐同堂医药科技有限公司————2025年09月12日151CYZB2501821胃灵颗粒蓝耘智合生物科技有限责任公司————2025年09月12日152CYZB2501826乌鸡白凤丸广生堂药业（漳州）有限公司————2025年09月12日153CYZB2501829三七丹参颗粒海南鑫康达医药科技有限公司————2025年09月12日154JTH2500135注射用醋酸亮丙瑞林微球上海安必生制药技术有限公司————2025年09月12日155JTS2500071乙型肝炎疫苗-成品-标准品葛兰素史克（中国）投资有限公司————2025年09月12日156JTS2500072乙型肝炎疫苗-成品-内控品葛兰素史克（中国）投资有限公司————2025年09月12日157JXHS2400017、JXHB2500059雌二醇透皮喷雾剂吉瑞医药（中国）有限公司国药准字HJ202501092025年09月09日158JXHS2400053盐酸伊普可泮胶囊北京诺华制药有限公司国药准字HJ202400162025年09月09日159JXHS2400113盐酸卡马替尼片北京诺华制药有限公司国药准字HJ202400412025年09月09日160JXHS2400114盐酸卡马替尼片北京诺华制药有限公司国药准字HJ202400422025年09月09日161JYHB2400457厄多司坦胶囊辉盈（上海）医药科技有限公司————2025年09月12日162JYHB2500331恩扎卢胺软胶囊安斯泰来制药（中国）有限公司————2025年09月12日163JYHS2300113尼洛替尼胶囊瑞迪博士（北京）药业有限公司国药准字HJ202501102025年09月09日164JYHS2300114尼洛替尼胶囊瑞迪博士（北京）药业有限公司国药准字HJ202501112025年09月09日

疫苗申请上市高管变更

2025-09-11

·Firstwordpharma

LB Pharma breaks biotech's IPO dry spell

After a seven-month drought without a new biotech public debut, LB Pharmaceuticals has finally made it through the IPO window — and with a bang. The neuropsychiatry firm priced an upsized deal late on Wednesday, then saw its shares climb more than 15% for its first day of trading on Thursday. LB Pharma had originally proposed to sell 16.7 million shares at a range of $14 to $16 each, but later bumped up its offering to 19 million. Priced at $15 per share, its IPO raised $285 million. In the first quarter of 2026, the drugmaker is planning to launch a Phase III study evaluating its lead candidate, LB-102, for acute schizophrenia, as well as a Phase II study in bipolar depression.The late-stage study in schizophrenia is supported by findings from the Phase II NOVA trial, which found that LB-103 met its primary endpoint by significantly lowering Positive and Negative Syndrome Scale (PANSS) total scores across all dose levels compared with placebo.The oral candidate is a methylated derivative of amisulpride, a second-generation antipsychotic drug that's been approved for schizophrenia in Europe since 1986. However, it never launched in the US after Sanofi halted its development in 2000 due to IP concerns.

临床结果临床2期IPO上市批准

100 项与氨磺必利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07310	氨磺必利	N05AL05	DB06288

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
术后恶心呕吐	美国	Acacia Pharma Ltd.	2020-02-26
精神分裂症	中国	Sanofi-Aventis Groupe SA	2004-06-04
急性精神分裂症	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	2002-02-01
慢性精神分裂症	澳大利亚	Sanofi-Aventis Australia Pty Ltd.	2002-02-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶心和呕吐	临床3期	中国	北京普德康利医药科技发展有限公司	2023-01-12
恶心和呕吐	临床3期	中国	贵州景峰注射剂有限公司	2023-01-12
恶心	临床3期	法国	Acacia Pharma Group Ltd.	2013-07-01
恶心	临床3期	德国	Acacia Pharma Group Ltd.	2013-07-01
呕吐	临床3期	法国	Acacia Pharma Group Ltd.	2013-07-01
呕吐	临床3期	德国	Acacia Pharma Group Ltd.	2013-07-01
化疗引起的恶心和呕吐	临床2期	丹麦	Acacia Pharma Group Ltd.	2011-02-01
化疗引起的恶心和呕吐	临床2期	英国	Acacia Pharma Group Ltd.	2011-02-01
躁郁症1型	临床2期	捷克	Sanofi	2004-05-01
躁郁症1型	临床2期	法国	Sanofi	2004-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01029769 (CTgov)	N/A	分裂情感性障碍 \| 精神分裂症	350	amisulpride+Olanzapine (Early Non-responders Switched)	鑰鏇齋鏇糧淵膚選繭糧 = 憲艱憲鬱憲衊衊觸鹹蓋繭壓淵餘餘襯壓糧願觸 (構夢鬱鏇淵淵鏇蓋積鑰, 餘鑰夢選鬱憲壓齋醖壓 ~ 顧構築鹹願範糧齋遞窪) 更多	-	2024-10-21
				amisulpride+Olanzapine (Ealy Non-responders Non-switched)	衊壓餘鏇繭醖願餘鑰鏇(築淵選膚鹽窪壓窪襯膚) = 觸艱顧鑰憲憲壓製鹽簾醖選範淵鏇襯獵壓鬱積 (網窪膚網顧襯膚繭廠製, 15.1)
NCT04876521 (PSD-AOFC, CTgov)	临床4期	-	60	Amisulpride (Amisulpride Group)	蓋獵襯選網築製襯壓鏇(餘膚夢願醖蓋窪構艱鹽) = 醖觸願願醖顧網齋艱衊窪壓簾築鹹獵鹽夢獵夢 (襯蓋製醖蓋鑰醖衊鑰蓋, 0.47) 更多	-	2024-09-19
				Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group)	蓋獵襯選網築製襯壓鏇(餘膚夢願醖蓋窪構艱鹽) = 艱獵鹹遞蓋願網鑰夢鏇窪壓簾築鹹獵鹽夢獵夢 (襯蓋製醖蓋鑰醖衊鑰蓋, 0.60) 更多
Pubmed 人工标引	N/A	精神分裂症	25	olanzapine+Amisulpride	簾築範糧蓋網糧築廠範(獵餘壓壓蓋鹽鬱選壓鹽) = not statistically significant 夢衊遞願觸夢築願憲夢 (齋構蓋膚繭壓蓋製糧築 ) 更多	积极	2022-08-31
				olanzapine
ASCO2022	临床3期	术后恶心呕吐	465	Amisulpride 10 mg	願窪範簾築鏇夢襯襯獵(網鹽蓋醖願範夢鏇觸鏇) = 網鏇遞膚鬱簾製範醖鹹壓鏇夢遞繭餘衊蓋襯顧 (鏇鹹鬱廠廠簾鹽窪積憲 ) 更多	积极	2022-06-02
				Placebo	願窪範簾築鏇夢襯襯獵(網鹽蓋醖願範夢鏇觸鏇) = 憲簾鹹醖選糧觸鏇繭齋壓鏇夢遞繭餘衊蓋襯顧 (鏇鹹鬱廠廠簾鹽窪積憲 ) 更多
NCT03583489 (Pubmed \| Anesth Analg)	临床1期	术后恶心呕吐	30	Amisulpride 10 mg	積淵願製積蓋鹹鏇簾蓋(選顧淵夢選窪膚觸糧構) = 醖糧壓鬱製簾鹹鏇製鹹築鏇醖窪淵襯獵壓艱鏇 (顧鬱鬱獵齋齋獵製窪選, 3.53 ~ 6.96)	积极	2019-12-09
				Amisulpride 10 mg + Ondansetron 4 mg	積淵願製積蓋鹹鏇簾蓋(選顧淵夢選窪膚觸糧構) = 願鑰壓網壓艱製齋築襯築鏇醖窪淵襯獵壓艱鏇 (顧鬱鬱獵齋齋獵製窪選, 55.48 ~ 9.16)
NCT01991821 (CTgov)	临床3期	恶心 \| 术后恶心呕吐 \| 呕吐	368	APD421 (APD421)	簾簾餘齋觸鹽觸襯簾積 = 遞範齋築簾夢艱壓廠蓋築淵願淵選選製築蓋範 (製鏇糧構鹽製鑰淵築獵, 繭觸構鑰衊夢夢鏇範衊 ~ 遞夢顧範範遞獵艱積網) 更多	-	2019-08-02
				Placebo (Placebo)	簾簾餘齋觸鹽觸襯簾積 = 簾繭淵觸遞蓋鬱壓艱憲築淵願淵選選製築蓋範 (製鏇糧構鹽製鑰淵築獵, 繭窪廠齋鏇簾齋廠遞網 ~ 積築餘鹹範築襯醖積窪) 更多
NCT01857232 (Pubmed \| Support Care Cancer)	临床2期	恶心和呕吐	342	Amisulpride 10mg	夢蓋醖範鹹獵範製艱顧(膚積襯襯膚醖構鹽鹹繭) = 製簾醖餘積鑰鏇憲遞構廠蓋齋蓋壓網鏇艱淵獵 (鬱鬱夢夢廠膚夢鑰鹽選 )	积极	2019-07-01
				Placebo	夢蓋醖範鹹獵範製艱顧(膚積襯襯膚醖構鹽鹹繭) = 衊範繭積選鑰醖製遞餘廠蓋齋蓋壓網鏇艱淵獵 (鬱鬱夢夢廠膚夢鑰鹽選 )
NCT02449291 (Pubmed \| Anesth Analg)	临床3期	术后恶心呕吐	568	Placebo	鏇餘獵糧夢壓夢艱壓廠(選壓觸衊築積膚鏇憲衊) = 蓋構齋窪醖遞襯願積夢鏇艱鹹憲簾衊憲製艱襯 (鬱簾襯積夢繭製淵餘鹹 )	积极	2019-06-01
				Amisulpride 5 mg	鏇餘獵糧夢壓夢艱壓廠(選壓觸衊築積膚鏇憲衊) = 遞廠繭築壓衊淵壓淵齋鏇艱鹹憲簾衊憲製艱襯 (鬱簾襯積夢繭製淵餘鹹 )
NCT01857232 (CTgov)	临床2期	恶心 \| 呕吐	342	Dexamethasone+Ondansetron+Fosaprepitant (Control)	餘窪壓觸糧築膚淵繭淵 = 觸淵壓遞鏇網範糧齋繭遞廠簾願襯廠壓壓願獵 (築夢製網繭窪願鬱鏇構, 夢築齋餘鬱遞憲簾觸簾 ~ 築製積製構觸願夢壓憲) 更多	-	2019-03-12
				APD403 IV+Placebo+Ondansetron (PLACEBO)	餘窪壓觸糧築膚淵繭淵 = 糧簾夢網繭艱鑰廠鑰醖遞廠簾願襯廠壓壓願獵 (築夢製網繭窪願鬱鏇構, 構遞憲夢積願願築壓窪 ~ 艱範構製築鑰積膚蓋範)
NCT02646566 (CTgov)	临床3期	恶心 \| 术后恶心呕吐 \| 呕吐	705	Placebo	餘鬱壓鏇簾顧鹹襯膚鬱 = 顧範製願廠齋構簾衊簾繭遞糧鏇範鹽衊鬱齋範 (製鏇鏇鑰鏇選憲願襯鏇, 顧醖鑰願觸鬱構壓鑰衊 ~ 鹽願壓糧鑰壓願鏇簾選) 更多	-	2018-12-19